Opinion|Videos|August 9, 2024
Key Takeaways and Clinical Pearls on the Treatment of R/R MM in the Era of Bispecifics
The panel concludes its discussion with key takeaways on the evolving treatment landscape for multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- What are some of your key takeaways and clinical pearls on the treatment of patients with relapsed/refractory multiple myeloma in the era of bispecifics?
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
3
Prizlon-cel Earns FDA RMAT and Fast Track Designations in Relapsed LBCL
4
Can AI Fix Clinical Trial Access in Oncology? Dr. Arturo Loaiza-Bonilla Built the Answer With the Data to Back It.
5